Le Lézard
Classified in: Health
Subjects: NEW PRODUCTS/SERVICES, HEALTH, GOVERNMENT CONTRACTS, LICENSING AGREEMENTS, MISCELLANEOUS

RavenQuest Awarded its First Cannabis Sales License from Health Canada


VANCOUVER, British Columbia, May 03, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the "Company" or "RavenQuest") a federally-licensed producer of cannabis, is pleased to announce it has secured a Health Canada sales license at the Company's Markham facility, also known as "Bloomera Inc." The license allows RavenQuest to commence sales of both medical and recreational cannabis nationwide.

Importantly, the license allows RavenQuest to route production from both its Markham and Edmonton facilities through Markham, effectively allowing all RavenQuest production to be sold through the Markham sales license.

"This is a major milestone for our company and is a testament to the hard work and dedication of our team," stated George Robinson, RavenQuest CEO. "It marks the beginning of our recreational cannabis presence as we roll out our branded product line, Lore Cannabistm. RavenQuest's brand will stand on the solid foundation of science and innovation. Our focus on the plant allows for consistent, repeatable and high-quality cannabis from our disruptive Orbital Gardens."

"We've been preparing for this day and have maintained an active dialogue with provincial wholesalers. This license opens the door for the next logical step of finalizing supply agreements with provincial wholesalers as well as the pursuit of European sales. Both our Edmonton and Markham facilities are built to European Good Manufacturing Practices (EU GMP) specification, and we are working vigorously toward that certification for both facilities. It's an exciting time at RavenQuest as our company enters a new era ? reaping the rewards of the research, investment and hard work of the past 18 months as we built the foundation for what is now a fully licensed and operational cannabis company," Robinson continued.

For more information, access RavenQuest's investor presentation, fact sheet and videos here.

Follow RavenQuest on Twitter @RQBGlobal

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

"George Robinson"
Chief Executive Officer

   
For further information, please contact: Mathieu McDonald, Corporate Communications
  1-877-282-1586
   

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to anticipated production capacity and quality. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.


These press releases may also interest you

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...

17 mai 2024
The Honourable Seamus O'Regan Jr., Minister of Labour and Seniors, on behalf of the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Tom Osborne, Newfoundland and Labrador's Minister of Health and Community Services will make...



News published on and distributed by: